Medicines Development for Global Health and the World Health Organization Special Programme for Research and Training in Tropical Diseases announced that the U.S. FDA approved moxidectin 8 mg oral for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older.
Merck announced today a $300,000 cash donation to support non-governmental organization partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF) in Africa.
